Search

Displaying results 3681 - 3690 of 8700 in total
  1. Drug

    Pemoline

    go.drugbank.com/drugs/DB01230
    ApprovedIllicitWithdrawn

    In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  2. Drug

    Ertiprotafib

    go.drugbank.com/drugs/DB06521
    Experimental

    Ertiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes. … In insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improved glycemic excursion during an oral glucose tolerance test.

  3. Drug

    Carindacillin

    go.drugbank.com/drugs/DB09319
    ApprovedWithdrawn

    Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of [carbenicillin] marketed by Pfizer as Geocillin. It is no longer marketed in the United States.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    MN-246

    go.drugbank.com/drugs/DB05981
    Experimental

    MN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.

  5. Drug

    NV-52

    go.drugbank.com/drugs/DB05673
    Experimental

    NV-52 is an investigational synthetic flavonoid thromboxane synthase (TXS) inhibitor developed for the maintenance of remission in inflammatory bowel disease.

  6. Drug

    Angiotensin II

    go.drugbank.com/drugs/DB11842
    ApprovedInvestigational

    As of December 21, 2017 the FDA approved La Jolla Pharmaceutical's Giapreza (angiotensin II) Injection for Intravenouse Infusion for the indication of acting as a vasoconstrictor to increase blood pressure … Angiotensin II is under investigation for the treatment of Sepsis, Septic Shock, Diabetes Mellitus, and Acute Renal Failure.

  7. Drug

    Chlorzoxazone

    go.drugbank.com/drugs/DB00356
    Approved

    It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  8. Drug

    Mebeverine

    go.drugbank.com/drugs/DB12554
    ApprovedInvestigationalWithdrawn

    Mebeverine has been investigated for the treatment of Irritable Bowel Syndrome and Post-cholecystectomy Gastrointestinal Spasms.

    Categories: Drugs for Functional Gastrointestinal Disorders
  9. Drug

    Praziquantel

    go.drugbank.com/drugs/DB01058
    ApprovedInvestigationalVet approved

    [A263201] The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030

    Mixtures: Eqvalan Duo Oral Paste for HorseCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  10. Drug

    Mirikizumab

    go.drugbank.com/drugs/DB14910
    ApprovedInvestigational

    [L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and was eventually approved in the US in October 2023[L48651] for the treatment of adult patients with … [L46237,L46257] Mirikizumab is approved in Japan[L46252] and received a positive opinion from the EMA's Committee for Medicinal Products for Human Use in March 2023.